Health Care
More on Health Care
Washington, D.C. (August 19, 2021)—Today, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform; Rep. Diana DeGette, Co-Chair of the Pro-Choice Caucus; Rep. Barbara Lee, Co-Chair of the Pro-Choice Caucus; and Rep.
Washington, D.C. (July 14, 2021)— Today, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, and Committee Members Rep. Robin Kelly and Rep. Cori Bush released a new Government Accountability Office (GAO) report on the public health impact of America's gun violence epidemic. Senator Elizabeth Warren and Senator Ed Markey joined the Members in highlighting the report and calling for Congress to act to protect Americans from gun violence.
Washington D.C. (July 12, 2021)—Today, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, and Rep. Frank Pallone, Jr., Chairman of the Committee on Energy and Commerce, sent a letter to Biogen Inc. Chief Executive Officer Michel Vounatsos requesting documents related to the approval process, marketing, and pricing of Biogen's Alzheimer's drug, Aduhelm.
Washington, D.C. (July 7, 2021)—On Thursday, July 8, 2021, at 2:00 p.m. ET, Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, will hold a press conference with Speaker Nancy Pelosi and advocates to release a new Oversight and Reform Committee staff report analyzing the financial data of 14 of the largest drug companies in the world to evaluate the amount they spend to enrich investors and executives, the amount they invest to research and develop new treatments, and the potential impact of direct Medicare price negotiations.
Washington D.C. (May 18, 2021)— Today, Rep. Carolyn B.
Washington, D.C. (May 18, 2021)— Today, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, Rep. Jerrold Nadler, Chairman of the Committee on the Judiciary, and Rep. David N.
Washington, D.C. (May 18, 2021)—Below is Committee on Oversight and Reform Chairwoman Carolyn B. Maloney's opening statement, as prepared for delivery, for today's full committee hearing examining the pricing and business practices of AbbVie Inc., which sells the anti-inflammatory drug Humira and the cancer drug Imbruvica.
Washington, D.C. (May 18, 2021)—Today, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, issued the following statement after releasing a staff report with new documents and details about AbbVie Inc., which sells the anti-inflammatory drug Humira and the cancer drug Imbruvica. AbbVie has repeatedly raised the prices of these two blockbuster drugs:
Washington D.C. (May 14, 2021)—On Tuesday, May 18, 2021, at 10:00 a.m., Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, will hold a hybrid hearing to examine the pricing and business practices of AbbVie Inc., which sells the anti-inflammatory drug Humira and the cancer drug Imbruvica.